%0 Generic
%B Drug Saf
%D 2021
%P 899-915
%R 10.1007/s40264-021-01095-7
%T Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
%V 44